L
Lewis J. Rubin
Researcher at University of California, San Diego
Publications - 373
Citations - 60316
Lewis J. Rubin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Pulmonary hypertension & Bosentan. The author has an hindex of 101, co-authored 370 publications receiving 57044 citations. Previous affiliations of Lewis J. Rubin include University of Texas Health Science Center at San Antonio & Silver Spring Networks.
Papers
More filters
Journal ArticleDOI
BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients.
TL;DR: This paper focuses on the use of Taxotere in lung cancer and head and neck cancer, and the research conducted in clinical trials by J.R.K. Dickinson and his colleagues.
Journal ArticleDOI
Cor Pulmonale Revisited. From Ferrer and Harvey to the Present
TL;DR: The right heart is no longer considered an "innocent bystander" in pulmonary hypertension, but rather a key component in its pathophysiology, and the status of right heart function is a major determinant of outcome.
Journal ArticleDOI
Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar1
Nazzareno Galiè,Marius M. Hoeper,Marc Humbert,Adam Torbicki,Jean-Luc Vachiery,Joan Albert Barberà,Maurice Beghetti,Paul A. Corris,Sean Gaine,J. Simon R. Gibbs,Miguel Ángel Gómez-Sánchez,Guillaume Jondeau,Walter Klepetko,Christian Opitz,Andrew J. Peacock,Lewis J. Rubin,Michael J. Zellweger,Gérald Simonneau +17 more
Journal ArticleDOI
Improving patient outcomes in pulmonary hypertension
TL;DR: The articles in this issue of European Respiratory Review discuss practical aspects of managing patients with PH, look at the disease from the patient perspective, and review some of the latest strategies for diagnosis and treatment of this group of conditions.
Journal ArticleDOI
A paradigm shift in pulmonary arterial hypertension management
TL;DR: The 6MWD is a simple, inexpensive, reproducible test that has allowed the rapid expansion of therapeutic options in PAH, and remains a valuable, clinically important measure of symptomatic improvement, but in today's more advanced PAH field, its utility as a primary end-point has been challenged.